Table 3

 Patients withdrawn from study (intent-to-treat population)

Primary reason for withdrawalNumber of patients withdrawn, n (%)
ETN (n = 159)ETN plus MTX (n = 155)
ETN, etanercept; MTX, methotrexate.
Adverse events6 (3.8)9 (5.8)
Unsatisfactory response9 (5.7)0 (0)
Death0 (0)2 (1.3)
Protocol violation1 (0.6)1 (0.6)
Patient request0 (0)1 (0.6)
Other event1 (0.6)0 (0)
Total17 (10.7)13 (8.4)